At the IGTP TODAY
Biointaxis, spin-off company from the Germans Trias i Pujol Research Institute (IGTP) has closed a financing round of 952,000 euros on the Capital Cell Platform. The company will use the investment to advance the pre-clinical research for their treatment for Friedriech's ataxia, a rare progressive degenerative disease. The studies aim to validate the safety of their treatment.
The biotechnology company Archivel Farma has designed and set up a phase IIb clinical study called CONSTAN to explore whether administering the immunotherapy RUTI®, known as the RUTI® vaccine, along with the standard treatment for patients with pulmonary tuberculosis (TB) improves results. The principal investigator of the project is Dr Cristina Vilaplana, leader of the Experimental Tuberculosis Unit (UTE) at the Germans Trias I Pujol Research Institute (IGTP). The study has been approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the First Patient In will be welcomed in January 2022
The Endocrine, Thyroid and Obesity Research Group led by Dr Manel Puig Domingo and the Universitat Rovira i Virgili (URV) spin-off company UP2SMART have created an artificial intelligence that can detect early facial changes in photographs. The software opens the door for an early detection system for acromegaly, a rare disease which produces deformities in facial and skeletal bone structure and has a range of other effects such as cardiac problems, diabetes and cancer. It is frequently diagnosed 10 years after onset, which leads to further complications.
Long-term exposure to air pollution is associated with a higher risk of developing COVID-19 among those people who get infected, shows the COVICAT Study led by the Barcelona Institute of Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, and co-led by the GCAT' Genomes for Life-Germans Trias i Pujol Research Institute (IGTP), Badalona. The study, published in Environment Health Perspectives, provides further evidence on the health benefits of reducing air pollution.
On 11-12 November the IV Workshop on translational research on urological tumours: from the laboratory to clinical practice took place at the Badalona Conference Centre (BCIN). They were jointly organized by the Germans Trias i Pujol Research Institute (IGTP) and the Badalona Applied Research Group in Oncology (B·ARGO), and the Institut Català d'Oncologia (ICO) and are scientifically accredited by SEOM and SOGUG.
A series of events to shine a light between the connection between art and science in times of pandemic. Events at the Can Manyé Cultural Centre in Alella and the Germans Trias i Pujol Hospital.
Today the VEIS website opens and the IGTP-GCAT is proud to be a member of the consortium. VEIS - Valorization of the EGA for Industry and Society is a step forward towards personalized medicine in Catalonia.
Dr Bonaventura Clotet, Director of IrsiCaixa and member of the Board of Trustees of the IGTP has been awarded the prestigious 'Premi Nacional de Recerca' in recognition of his contribution to science with his work on infectious diseases, especially HIV and AIDS.
The CIBERES collection, within the Pulmonary Biobank Platform, has been housed in the IGTP-HUGTP Biobank since 2012. The Pulmonary Biobank Platform finances the audit necessary for the certification, which is required for all their collections. The certificate covers the collection, processing and storage and distribution of biological samples in respiratory medicine.
A study coordinated by researchers of the Centre for Epidemiological Studies of Sexually Transmitted Disease and AIDS in Catalonia (CEEISCAT) a research group affiliated with and based at the Germans Trias i Pujol Research Institute (IGTP) publish a paper in the HIV Lancet showing the risk factors for suffering severe covid-19 for people living with HIV in Catalonia. The results show that people living with HIV at the same time as other chronic diseases and unsuppressed viral loads have a higher risk of suffering severe covid-19 and should be given priority for testing, medical management and vaccination programmes to protect against SARS-CoV-2.
